Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
Understand how particle size impacts inhalation drug delivery and the role of dry powder inhalers (DPIs) in treating respiratory diseases.
The Role of In Silico Regional Deposition Modelling and Pharmacokinetic Profiling in the Development of a Generic Tiotropium Dry Powder Inhaler
Nanopharm explores In Silico methods in the development of a Generic Tiotropium Dry Powder Inhaler (DPI). Learn how drug absorption is impacted.
In Vitro and In Silico Comparison of Indacaterol and Glycopyrrolate Pulmonary Deposition between a Single-Unit Dose and a Multi-Unit Dry Powder Inhaler
In-depth study by Nanopharm on In Vitro and In Silico comparison of Indacaterol and Glycopyrrolate in single-unit and multi-unit DPIs for COPD treatment.
Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges
Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.
Elucidating Molecular- and Particle-Level Changes during the Annealing of a Micronized Crystalline Drug
Nanopharm explores annealing in micronized DPIs for drug development. Focus on molecular changes and SFE in Dry Powder Inhaler formulations.
The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate
Nanopharm explores structural dynamics of Fluticasone Propionate in DPIs. Focus on APSD in Dry Powder Inhaler formulations.
Structural Dynamics of Fluticasone Propionate Processing
Nanopharm explores the effect of secondary processing on the structural relaxation dynamics of Fluticasone Propionate.
